`Noven Pharmaceuticals, Inc.
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`_________________________________
`
`
`Inter Partes Review No.: 2014-00550
`U.S. Patent No. 6,335,031
`
`
`Declaration of Christopher J. Coulson Regarding
`Exhibits 1044 and 1045
`
`Noven Exhibit 1043
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`1 of 2
`
`
`
`I, Christopher J. Coulson, declare as follows:
`
`1. I am an attorney at Kenyon and Kenyon LLP, counsel for Petitioner
`
`Noven Pharmaceuticals, Inc. (“Petitioner”) in the above-captioned inter partes
`
`review. My attorney registration number is 61,771. I respectfully submit this
`
`declaration in support of Petitioner’s Exhibit 1044 and 1045.
`
`2. Exhibit 1044 is a true and correct copy of search results I caused to be
`
`obtained by entry the search term “rivastigmine-d6 tartrate” into the quick search
`
`window on the Toronto Research Chemicals Inc. website (available at
`
`https://www.trc-canada.com/index.php) followed by selection of “Details/Order”
`
`for rac Rivastigmine-d6 Tartrate Salt on March 23, 2015.
`
`3. Exhibit 1045 is a true and correct copy of an article that I caused to be
`
`downloaded on March 24, 2015 from The Times of Israel website (available at
`
`www.timesofisrael.com), entitled “Alzheimer drug pioneer to get Israel Prize”.
`
`I declare under penalty of perjury under the laws of the United States of
`
`America that the foregoing is true and correct. I understand that willful false
`
`statements are punishable by fine or imprisonment or both. See 18 U.S.C. § 1001.
`
`Dated: March 31 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Christopher J. Coulson
`Christopher J. Coulson
`
`
`
`
`
`Noven Exhibit 1043
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`2 of 2
`
`